• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ARID 家族成员在乳腺癌中的表达及预后价值。

Expression and prognostic values of ARID family members in breast cancer.

机构信息

Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.

Department of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

出版信息

Aging (Albany NY). 2021 Feb 11;13(4):5621-5637. doi: 10.18632/aging.202489.

DOI:10.18632/aging.202489
PMID:33592583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7950271/
Abstract

The ARID family is a superfamily of 15 members containing a domain that interacts with AT-rich DNA elements. However, the expression and prognostic roles of each ARID in breast cancer are still elusive. We used the TCGA and Kaplan-Meier plotter databases to assess the expression and prognostic values of ARID mRNA levels in breast cancer respectively. In the present study, 6 members were significantly lower in tumor tissues than those in the normal tissues, while 6 members were significantly higher. Further assessment of ARID expression in breast cancer with different molecular subtypes, 3 members were significantly higher in no-luminal molecular subtype than those in the luminal molecular subtype, and 6 members were significantly higher. In regard to prognostic values, high expression of ARID1A, ARID2, ARID3B, ARID4A, ARID5A, ARID5B, JARID1A were associated with favorable outcome, while ARID4B and JARID1B were correlated to a worse outcome. We further analyzed the prognostic value of ARID in different intrinsic subtypes and clinicopathological features of breast cancer. We found many meaningful ARID family biomarkers in breast cancer. The relevant results will expound the role of ARID in breast cancer and may further provide new insight to explore the ARID-targeting reagents for treating breast cancer patients.

摘要

ARID 家族是一个包含与富含 AT 的 DNA 元件相互作用的结构域的 15 个成员的超家族。然而，每个 ARID 在乳腺癌中的表达和预后作用仍不清楚。我们分别使用 TCGA 和 Kaplan-Meier plotter 数据库评估 ARID mRNA 水平在乳腺癌中的表达和预后价值。在本研究中，有 6 个成员在肿瘤组织中的表达明显低于正常组织，而有 6 个成员的表达明显升高。进一步评估 ARID 在不同分子亚型乳腺癌中的表达，有 3 个成员在非腔面分子亚型中的表达明显高于腔面分子亚型，而有 6 个成员的表达明显升高。至于预后价值，ARID1A、ARID2、ARID3B、ARID4A、ARID5A、ARID5B 的高表达与良好的预后相关，而 ARID4B 和 JARID1B 与较差的预后相关。我们进一步分析了 ARID 在乳腺癌不同内在亚型和临床病理特征中的预后价值。我们在乳腺癌中发现了许多有意义的 ARID 家族生物标志物。相关结果将阐述 ARID 在乳腺癌中的作用，并可能进一步为探索针对 ARID 的靶向试剂治疗乳腺癌患者提供新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8001/7950271/220ac1d29715/aging-13-202489-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8001/7950271/d76ca543bc71/aging-13-202489-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8001/7950271/82544394507a/aging-13-202489-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8001/7950271/e95242691d7a/aging-13-202489-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8001/7950271/5c547dde0e34/aging-13-202489-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8001/7950271/0ed281fb0435/aging-13-202489-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8001/7950271/871e247cc0e5/aging-13-202489-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8001/7950271/220ac1d29715/aging-13-202489-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8001/7950271/d76ca543bc71/aging-13-202489-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8001/7950271/82544394507a/aging-13-202489-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8001/7950271/e95242691d7a/aging-13-202489-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8001/7950271/5c547dde0e34/aging-13-202489-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8001/7950271/0ed281fb0435/aging-13-202489-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8001/7950271/871e247cc0e5/aging-13-202489-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8001/7950271/220ac1d29715/aging-13-202489-g007.jpg

相似文献

1
Expression and prognostic values of ARID family members in breast cancer.ARID 家族成员在乳腺癌中的表达及预后价值。
Aging (Albany NY). 2021 Feb 11;13(4):5621-5637. doi: 10.18632/aging.202489.
2
Comprehensive Landscape of ARID Family Members and Their Association with Prognosis and Tumor Microenvironment in Hepatocellular Carcinoma.ARID 家族成员的全面分析及其与肝细胞癌预后和肿瘤微环境的关系。
J Immunol Res. 2022 Mar 30;2022:1688460. doi: 10.1155/2022/1688460. eCollection 2022.
3
Distinct prognostic values of S100 mRNA expression in breast cancer.乳腺癌中 S100mRNA 表达的不同预后价值。
Sci Rep. 2017 Jan 4;7:39786. doi: 10.1038/srep39786.
4
The Prognostic Value of AT-Rich Interaction Domain (ARID) Family Members in Patients with Hepatocellular Carcinoma.富含AT序列相互作用结构域（ARID）家族成员在肝细胞癌患者中的预后价值
Evid Based Complement Alternat Med. 2022 Aug 18;2022:1150390. doi: 10.1155/2022/1150390. eCollection 2022.
5
Expression Pattern and Prognostic Value of EPHA/EFNA in Breast Cancer by Bioinformatics Analysis: Revealing Its Importance in Chemotherapy.基于生物信息学分析的乳腺癌中 EphA/EFNA 的表达模式及其预后价值：揭示其在化疗中的重要性。
Biomed Res Int. 2021 Apr 22;2021:5575704. doi: 10.1155/2021/5575704. eCollection 2021.
6
Prognostic characterization of OAS1/OAS2/OAS3/OASL in breast cancer.OAS1/OAS2/OAS3/OASL 在乳腺癌中的预后特征。
BMC Cancer. 2020 Jun 19;20(1):575. doi: 10.1186/s12885-020-07034-6.
7
The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.组蛋白伴侣HJURP是腔面A型乳腺癌一种新的独立预后标志物。
Mol Oncol. 2015 Mar;9(3):657-74. doi: 10.1016/j.molonc.2014.11.002. Epub 2014 Nov 20.
8
Expression of Protein 4.1 Family in Breast Cancer: Database Mining for 4.1 Family Members in Malignancies.蛋白 4.1 家族在乳腺癌中的表达：数据库挖掘恶性肿瘤中的 4.1 家族成员。
Med Sci Monit. 2019 May 7;25:3374-3389. doi: 10.12659/MSM.914085.
9
Downregulation of ARID4A and ARID4B promote tumor progression and directly regulated by microRNA-30d in patient with prostate cancer.ARID4A 和 ARID4B 的下调促进了前列腺癌患者的肿瘤进展，并且直接受 microRNA-30d 的调控。
J Cell Biochem. 2018 Sep;119(9):7245-7255. doi: 10.1002/jcb.26913. Epub 2018 May 24.
10
CD24 is a Potential Biomarker for Prognosis in Human Breast Carcinoma.CD24是人类乳腺癌预后的潜在生物标志物。
Cell Physiol Biochem. 2018;48(1):111-119. doi: 10.1159/000491667. Epub 2018 Jul 12.

引用本文的文献

1
ARID1A: gene, protein, and function in endometrial cancer.ARID1A：子宫内膜癌中的基因、蛋白质及功能
Oncogene. 2025 Aug 18. doi: 10.1038/s41388-025-03539-1.
2
ARID4B: An Orchestrator from Stem Cell Fate to Carcinogenesis.ARID4B：从干细胞命运到肿瘤发生的调控因子
Cells. 2025 Jun 10;14(12):872. doi: 10.3390/cells14120872.
3
Arid4a Suppresses Breast Tumor Metastasis by Enhancing MTSS1 Expression via mRNA Stability.Arid4a通过增强mRNA稳定性来提高MTSS1表达，从而抑制乳腺肿瘤转移。

本文引用的文献

1
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.ARID1A 决定了雌激素受体阳性乳腺癌的腔面特征和治疗反应。
Nat Genet. 2020 Feb;52(2):198-207. doi: 10.1038/s41588-019-0554-0. Epub 2020 Jan 13.
2
HuR Reduces Radiation-Induced DNA Damage by Enhancing Expression of ARID1A.HuR通过增强ARID1A的表达减少辐射诱导的DNA损伤。
Cancers (Basel). 2019 Dec 13;11(12):2014. doi: 10.3390/cancers11122014.
3
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.
Cancer Med. 2025 Mar;14(5):e70732. doi: 10.1002/cam4.70732.
4
Construction and evaluation of a multifactorial clinical model for discriminating benign and malignant breast tumors using LASSO algorithm based on retrospective cohort study.基于回顾性队列研究，使用LASSO算法构建并评估用于鉴别乳腺良恶性肿瘤的多因素临床模型
Am J Cancer Res. 2024 Dec 15;14(12):5628-5643. doi: 10.62347/ILIJ7959. eCollection 2024.
5
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer.描绘HER2抑制剂耐药的生物标志物：对HER2阳性乳腺癌治疗的启示
Cancers (Basel). 2024 Jul 24;16(15):2635. doi: 10.3390/cancers16152635.
6
Non-apoptotic regulatory cell death scoring system to predict the clinical outcome and drug choices in breast cancer.用于预测乳腺癌临床结局和药物选择的非凋亡调节性细胞死亡评分系统
Heliyon. 2024 May 16;10(10):e31342. doi: 10.1016/j.heliyon.2024.e31342. eCollection 2024 May 30.
7
Research progress of SWI/SNF complex in breast cancer.SWI/SNF 复合物在乳腺癌中的研究进展。
Epigenetics Chromatin. 2024 Feb 17;17(1):4. doi: 10.1186/s13072-024-00531-z.
8
Heterozygous Knockout of Using CRISPR/Cas9 Attenuates Some Aggressive Phenotypes in a Breast Cancer Cell Line.CRISPR/Cas9 介导的杂合敲除 可减轻乳腺癌细胞系的某些侵袭表型。
Genes (Basel). 2023 Dec 6;14(12):2184. doi: 10.3390/genes14122184.
9
Copy number variants landscape of multiple cancers and clinical applications based on NGS gene panel.基于 NGS 基因 panel 的多种癌症拷贝数变异景观及其临床应用。
Ann Med. 2023;55(2):2280708. doi: 10.1080/07853890.2023.2280708. Epub 2023 Nov 15.
10
Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study.动态循环肿瘤 DNA 分析预测转移性三阴性乳腺癌患者的预后和监测治疗反应：一项前瞻性研究。
Elife. 2023 Nov 6;12:e90198. doi: 10.7554/eLife.90198.
曲妥珠单抗-美坦新偶联物（T-DM1）耐药的机制：HER2 阳性乳腺癌。
Br J Cancer. 2020 Mar;122(5):603-612. doi: 10.1038/s41416-019-0635-y. Epub 2019 Dec 16.
4
Upregulated expression of AT-rich interactive domain-containing protein 1B predicts poor prognosis in patients with triple-negative breast cancer.富含AT序列相互作用结构域蛋白1B的表达上调预示三阴性乳腺癌患者预后不良。
Oncol Lett. 2019 Mar;17(3):3289-3295. doi: 10.3892/ol.2019.9961. Epub 2019 Jan 23.
5
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
6
ARID1A and CEBPα cooperatively inhibit UCA1 transcription in breast cancer.ARID1A 和 CEBPα 协同抑制乳腺癌中的 UCA1 转录。
Oncogene. 2018 Nov;37(45):5939-5951. doi: 10.1038/s41388-018-0371-4. Epub 2018 Jul 6.
7
Downregulation of ARID4A and ARID4B promote tumor progression and directly regulated by microRNA-30d in patient with prostate cancer.ARID4A 和 ARID4B 的下调促进了前列腺癌患者的肿瘤进展，并且直接受 microRNA-30d 的调控。
J Cell Biochem. 2018 Sep;119(9):7245-7255. doi: 10.1002/jcb.26913. Epub 2018 May 24.
8
Identification of upstream transcription factors (TFs) for expression signature genes in breast cancer.乳腺癌中表达特征基因上游转录因子的鉴定。
Gynecol Endocrinol. 2017 Mar;33(3):193-198. doi: 10.1080/09513590.2016.1239253. Epub 2016 Nov 4.
9
Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge.FTO在罕见的全耐药三阴性炎性乳腺癌细胞应对严峻代谢挑战时存活中的重要作用
PLoS One. 2016 Jul 8;11(7):e0159072. doi: 10.1371/journal.pone.0159072. eCollection 2016.
10
Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.ARID1A 缺失激活 ANXA1，后者可作为曲妥珠单抗耐药的预测性生物标志物。
Clin Cancer Res. 2016 Nov 1;22(21):5238-5248. doi: 10.1158/1078-0432.CCR-15-2996. Epub 2016 May 12.